Short Course Terlipressin for Control of Acute Variceal Bleeding
Launched by AGA KHAN UNIVERSITY · Aug 24, 2006
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
The esophageal variceal bleeding is usually controlled with endoscopic treatment of variceal band ligation or sclerotherapy along with vasoactive drugs like Terlipressin or Octreotide. The risk of re-bleeding is highest during the initial 5 days from first presentation. Terlipressin is usually given for 3 days (72 hours). In this study we are trying to prove that among low to moderate risk patients, a short course of 1 day (24 hours) of Terlipressin is as effective as 3 days (72 hours) in preventing re-bleed once bleeding has been controlled with endoscopic therapy. This intervention will s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute esophageal variceal bleed
- • Liver cirrhosis
- • Child's score \</= 11
- Exclusion Criteria:
- • Patient on Mechanical ventilator and or ionotropic support
- • Active angina, Recent Myocardial infarction or dynamic EKG changes
- • Failure to control variceal bleed on initial endoscopy
- • Gastric variceal bleed
- • Spontaneous bacterial peritonitis at presentation
- • Hepatocellular carcinoma or other liver metastatic malignancy
- • Portal vein thrombosis
About Aga Khan University
Aga Khan University (AKU) is a distinguished institution dedicated to improving health and education across developing regions. Established in 1983, AKU is recognized for its commitment to research excellence, particularly in clinical trials that address pressing health issues in diverse populations. With a focus on advancing medical knowledge and practice, AKU's clinical trial initiatives are designed to foster innovative solutions and enhance patient care. The university collaborates with various local and international partners, leveraging its multidisciplinary expertise to conduct rigorous research that informs public health policy and improves health outcomes in communities served by its facilities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Saeed S Hamid, FRCP, FACG
Study Chair
The Aga Khan University Hospital
Zahid SM Azam, MBBS, FCPS
Study Director
The Aga Khan University Hospital
Wasim SM Jafri, FRCP, FACG
Study Director
The Aga Khan University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials